Skip to content
2000
Volume 17, Issue 1
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Minimal residual disease (MRD) detection represents a great advancement in multiple myeloma. New drugs are now available that increase depth of response. The International Myeloma Working Group recommends using next-generation flow cytometry (NGF) or next-generation sequencing (NGS) to search for MRD in clinical trials. Best sensitivity thresholds have to be confirmed, as well as timing to detect it. MRD has proven as the best prognosticator in many trials and promises to enter also in clinical practice to guide future therapy.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/1574887116666211123092915
2022-02-01
2024-11-14
Loading full text...

Full text loading...

/content/journals/rrct/10.2174/1574887116666211123092915
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test